BTIG analyst Thomas Shrader downgraded INmune Bio Inc. (NASDAQ: INMB) from Buy to Neutral.The analyst comments "A solid MAYBE but ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Form 8-K Inmune Bio, Inc. For: Jun 27June 30, 2025 4:31 PM INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 30, 2025 4:05 PM Lucid Capital Markets Downgrades INmune Bio Inc. (INMB) to NeutralJune 30, 2025 4:01 PM INmune Bio (INMB) call put ratio 1 call to 1.7 puts with a focus on July 2.5 put as share price down 59.9%June 30, 2025 2:24 PM Raymond James Downgrades INmune Bio Inc. (INMB) to Market PerformJune 30, 2025 1:49 PM Increasing unusual call option volume: CFG INMB KBE TRIP TAP JNPR FEZ VNET PUBM JOBY NEXT FLNC June 30, 2025 10:36 AM Form 424B5 Inmune Bio, Inc. June 30, 2025 9:15 AM Form 8-K Inmune Bio, Inc. For: Jun 30June 30, 2025 8:02 AM INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial resultsJune 30, 2025 7:48 AM INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumbleJune 30, 2025 7:41 AM INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XProJune 30, 2025 7:30 AM INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s DiseaseJune 30, 2025 7:30 AM INmune Bio (INMB) Announces Approximately $19 Million Registered Direct OfferingJune 27, 2025 12:16 PM INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 27, 2025 12:16 PM After-hours movers: Nike, American Outdoor Brands and moreJune 26, 2025 4:42 PM INmune Bio (INMB) to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30thJune 26, 2025 4:01 PM Form 8-K Inmune Bio, Inc. For: Jun 26June 26, 2025 4:01 PM INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30thJune 26, 2025 4:00 PM